



## Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma


### SUPPLEMENTARY FIGURES




Supplementary Figure S1: CHK1 expression is lower in proliferating murine cerebellum compared to Group 3 medulloblastoma cell line as measured by qRT-PCR.



**Supplementary Figure S2: CHK1 expression is not correlated with adverse outcomes in Group 4/SHH medulloblastoma patients.** Kaplan-Meier survival curve shows no significant change in long-term survival of group 4/SHH medulloblastoma patients with increased CHK1 expression.



**Supplementary Figure S3: Western blot of CHK2 and p53 phosphorylation in response to two different CHK1 inhibitors.** AZD7761 suppresses phosphoCHK1 but not pCHK2 while PF477736 suppresses phosphorylation of both CHK1 and CHK2. Both inhibitors induce phosphorylation of p53.



**Supplementary Figure S4: AZD7762 reduces cell proliferation capacity and increases apoptotic rate.** **A.** Real-time mCherry signal of Daoy cells transfected with mCherry after AZD7762 treatment. **B.** Real-time GFP Caspase-3/7 signal of Daoy cells treated with AZD7762.